Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intelligent Bio Solutions (INBS) Total Liabilities (2019 - 2025)

Intelligent Bio Solutions has reported Total Liabilities over the past 6 years, most recently at $5.6 million for Q2 2024.

  • For Q2 2024, Total Liabilities fell 16.08% year-over-year to $5.6 million; the TTM value through Jun 2024 reached $5.6 million, down 16.08%, while the annual FY2024 figure was $5.6 million, 16.08% down from the prior year.
  • Total Liabilities for Q2 2024 was $5.6 million at Intelligent Bio Solutions, down from $6.0 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $7.8 million in Q4 2022 and troughed at $1.2 million in Q4 2020.
  • A 5-year average of $5.4 million and a median of $5.7 million in 2022 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: crashed 79.84% in 2020 and later soared 338.3% in 2021.
  • Year by year, Total Liabilities stood at $1.2 million in 2020, then soared by 338.3% to $5.2 million in 2021, then skyrocketed by 49.97% to $7.8 million in 2022, then dropped by 27.13% to $5.7 million in 2023, then dropped by 1.36% to $5.6 million in 2024.
  • Business Quant data shows Total Liabilities for INBS at $5.6 million in Q2 2024, $6.0 million in Q1 2024, and $5.7 million in Q4 2023.